Wall Street analysts expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) to report earnings of $0.35 per share for the current quarter, Zacks reports. Two analysts have issued estimates for Opiant Pharmaceuticals’ earnings. The highest EPS estimate is $0.60 and the lowest is $0.10. Opiant Pharmaceuticals posted earnings of ($0.37) per share in the same quarter last year, which would suggest a positive year over year growth rate of 194.6%. The firm is expected to announce its next quarterly earnings report on Thursday, March 19th.
On average, analysts expect that Opiant Pharmaceuticals will report full-year earnings of $2.47 per share for the current year, with EPS estimates ranging from $2.05 to $3.14. For the next fiscal year, analysts forecast that the company will report earnings of ($0.29) per share, with EPS estimates ranging from ($2.65) to $3.21. Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for Opiant Pharmaceuticals.
Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Tuesday, November 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.87. The business had revenue of $20.64 million during the quarter, compared to analyst estimates of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%.
Separately, Northland Securities reiterated a “buy” rating and issued a $42.00 price objective on shares of Opiant Pharmaceuticals in a research report on Thursday, November 7th.
In other Opiant Pharmaceuticals news, Director Ann L. Macdougall acquired 5,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $13.51 per share, for a total transaction of $67,550.00. Also, insider Phil Skolnick sold 7,143 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $13.47, for a total value of $96,216.21. Insiders purchased 7,885 shares of company stock valued at $106,604 over the last quarter. 30.88% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Opiant Pharmaceuticals by 93.5% during the second quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock worth $276,000 after purchasing an additional 10,045 shares in the last quarter. Morgan Stanley lifted its stake in Opiant Pharmaceuticals by 1,000.3% during the second quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock worth $297,000 after purchasing an additional 20,377 shares in the last quarter. Stonepine Capital Management LLC lifted its stake in Opiant Pharmaceuticals by 7.0% during the second quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock worth $4,180,000 after purchasing an additional 20,574 shares in the last quarter. Finally, Wedge Capital Management L L P NC acquired a new position in Opiant Pharmaceuticals during the third quarter worth $363,000. Institutional investors own 21.49% of the company’s stock.
Shares of Opiant Pharmaceuticals stock opened at $13.45 on Friday. The firm has a market capitalization of $54.85 million, a price-to-earnings ratio of -1.89 and a beta of 0.23. Opiant Pharmaceuticals has a fifty-two week low of $9.98 and a fifty-two week high of $18.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.28 and a current ratio of 4.28. The stock has a 50 day moving average of $14.10 and a 200 day moving average of $14.21.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.